Pacific Biosciences of California, Inc. Stock
Stocks
PACB
US69404D1081
Advanced Medical Equipment & Technology
|
Real-time Estimate
Cboe BZX
17:54:31 16/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 1.815 USD | -7.40% |
|
-22.32% | -3.21% |
| Market Cap | 609M 544M 505M 460M 865M 57.7B 881M 6.07B 2.38B 30.11B 2.29B 2.24B 96.34B | P/E 2026 * |
-4.43x | P/E 2027 * | -4.26x |
|---|---|---|---|---|---|
| Enterprise Value | 1.08B 962M 894M 814M 1.53B 102B 1.56B 10.74B 4.2B 53.28B 4.05B 3.96B 170B | EV / Sales 2026 * |
6.79x | EV / Sales 2027 * | 6.17x |
| Free-Float |
91.14% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| PACB | Delayed | |
CBOE
| PACB | Real-time | |
Tradegate
| P09 | Real-time | |
Mexican S.E.
| PACB * | End-of-day quote | |
Boerse Muenchen
| P09 | Real-time | |
Deutsche Boerse AG
| P09 | Delayed | |
Börse Stuttgart
| P09 | Delayed |
Last Transcript: Pacific Biosciences of California, Inc.
| 1 day | -1.51% | ||
| 1 week | -14.78% | ||
| Current month | -17.30% | ||
| 1 month | +46.27% | ||
| 3 months | +28.10% | ||
| 6 months | +22.50% | ||
| Current year | +4.81% |
| 1 week | 1.86 | 2.29 | |
| 1 month | 1.34 | 3.44 | |
| Current year | 1.07 | 3.44 | |
| 1 year | 1.07 | 3.44 | |
| 3 years | 0.85 | 10.65 | |
| 5 years | 0.85 | 31.1 | |
| 10 years | 0.85 | 53.69 |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark van Oene
CEO | Chief Executive Officer | 53 | 05/08/2026 |
Jim Gibson
DFI | Director of Finance/CFO | 57 | 31/03/2025 |
Jonas Korlach
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2012 |
| Director | Title | Age | Since |
|---|---|---|---|
Bill Ericson
BRD | Director/Board Member | 67 | 01/01/2004 |
Randy Livingston
BRD | Director/Board Member | 72 | 01/01/2009 |
Marshall Mohr
BRD | Director/Board Member | 69 | 18/01/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/6/26 A | Exercice | Chief Financial Officer | 1,661,815 | 0.5346% | ||
| 8/17/26 A | Sell | Chief Executive Officer | -26,911 | 0.0087% | ||
| 8/10/26 A | Free | Chief Executive Officer | 2,457,018 | 0.7911% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.51% | -14.78% | +12.64% | -75.44% | 609M | ||
| +3.46% | +6.83% | +31.94% | +44.25% | 258B | ||
| +3.03% | +6.46% | +12.32% | +10.54% | 163B | ||
| +1.81% | +3.00% | -1.78% | +56.64% | 151B | ||
| +2.65% | +5.00% | -54.83% | -10.86% | 63.97B | ||
| +1.91% | +4.58% | +20.80% | +24.47% | 50.78B | ||
| +1.51% | +6.00% | -12.85% | -12.96% | 50.94B | ||
| +0.89% | +4.39% | +25.71% | +58.85% | 49.49B | ||
| +5.27% | +9.90% | +8.93% | +44.85% | 50.68B | ||
| +1.73% | +3.50% | +33.62% | +75.82% | 43.64B | ||
| Average | +1.51% | +2.71% | +7.65% | +21.62% | 88.15B | |
| Weighted average by Cap. | +1.78% | +4.03% | +11.41% | +34.04% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 159M 142M 132M 120M 225M 15.03B 229M 1.58B 619M 7.84B 596M 583M 25.1B | 184M 164M 153M 139M 261M 17.44B 266M 1.83B 718M 9.1B 691M 676M 29.11B |
| Net income | -138M -123M -114M -104M -195M -13.03B -199M -1.37B -536M -6.8B -516M -505M -21.75B | -147M -131M -122M -111M -209M -13.93B -213M -1.47B -573M -7.27B -552M -540M -23.25B |
| Net Debt | 469M 419M 389M 354M 666M 44.41B 678M 4.67B 1.83B 23.17B 1.76B 1.72B 74.15B | 527M 470M 437M 397M 748M 49.87B 761M 5.25B 2.05B 26.02B 1.98B 1.93B 83.27B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/10/26 | $1.804 | -7.97% | 2,026,062 |
| 15/10/26 | $1.960 | -1.51% | 12,620,912 |
| 14/10/26 | $1.990 | -2.93% | 9,205,009 |
| 13/10/26 | $2.050 | -2.38% | 12,286,886 |
| 12/10/26 | $2.100 | -9.87% | 12,083,875 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PACB Stock
Select your edition
All financial news and data tailored to specific country editions

















